Get these analyses to your inbox — https://axialfc.substack.com/ This is a newsletter for new financing events with some simple analysis. More well thought out work can be found at — https://axial.substack.com/ I figured that there is a diversity across desire for frequency of emails.
Axial invests and partners in early-stage life sciences companies. If you or someone you know has a great idea or company in life sciences, Axial would be excited to get to know you and possibly invest in your vision and company — info@axialsprawl.com
April 4, 2020 — April 10, 2020
Financings
Number of deals: 22 & Total capital invested: $739M
- 98point6 raised $43M from Goldman Sachs and others. The company has a text-based mobile app to help patients get primary care. The idea is interesting but probably not valuable as a standalone — primary care is something like 10% of network/hospital revenue. This is more of a leadgen tool for them so 98point6 will need to expand to referrals and other tasks to grow into a large business.
- Amphista Therapeutics raised $7.5M led by Advent Venture Partners. The company is another one to put their hat in the ring for protein degradation for oncology similar to Arvinas and others — https://www.insider.co.uk/news/amphista-therapeutics-secures-6m-funding-21826354
- Arrakis Therapeutics raised $190M in strategic funding from Roche. The…
